NCT04555213View on ClinicalTrials.gov

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions

Covid19

Interventions

DRUG

NOX66

NOX66 Suppository

Trial Locations (1)

Unknown

Institute of Emergency Medicine, Chisinau

Sponsors

Lead Sponsor

Noxopharm Limited

All Listed Sponsors

lead

Noxopharm Limited

INDUSTRY